Brief: United Therapeutics Corporation Announces Teton-1 Pivotal Study Of Tyvaso® Meets Primary Endpoint For Treatment Of Idiopathic Pulmonary Fibrosis, Exceeding Impressive Treatment Effect Seen In Teton-2
30/03/2026 14:23
March 30 (Reuters) - United Therapeutics Corp UTHR.O: UNITED THERAPEUTICS CORPORATION ANNOUNCES TETON-1 PIVOTAL STUDY OF TYVASO® MEETS PRIMARY ENDPOINT FOR TREATMENT OF IDIOPATHIC PULMONARY FIBROSIS, EXCEEDING IMPRESSIVE TREATMENT EFFECT SEEN IN TETON-2 UNITED THERAPEUTICS CORP - TYVASO BENEFITS OBSERVED ACROSS ALL SUBGROUPS WITH NO NEW SAFETY SIGNALS UNITED THERAPEUTICS CORP - PLANS TO SEEK PRIORITY REVIEW OF SNDA FOR TYVASO, TO BE SUBMITTED TO FDA BY END OF THIS SUMMER Source text: ID:nBw3Wblh8a Further company coverage: UTHR.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on United Therapeutics
See all newsBrief: United Therapeutics Corporation Announces Additional $2 Billion Share Repurchase Authorization
Brief: United Therapeutics Announces FDA Clearance To Proceed With Summit Clinical Trial For Treprostinil Smi In Ph-Copd
Liquidia surges as United Therapeutics settlement removes key litigation risk (updated)
Brief: United Therapeutics Enters Settlement Agreement With Liquidia To Resolve Litigation - SEC Filing
Liquidia surges after $381 million settlement with United Therapeutics for lung disease drug